Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 12/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.33 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105533 | 0.86 | PARP1 (0.36) | PLA2G7GRM2 | |
| SCHEMBL9106147 | 0.85 | VNN1 (0.38) | DAOPLA2G7GRM2 | |
| SCHEMBL27924951 | 0.85 | MPO (0.33) | PLA2G7GRM2RIPK3TP53MDM2 | |
| SCHEMBL9900505 | 0.83 | PDE3B (0.36) | DAOPLA2G7GRM2RIPK3 | |
| SCHEMBL9105050 | 0.80 | PLA2G7 (0.46) | PLA2G7 | |
| SCHEMBL9108512 | 0.79 | PLA2G7 (0.40) | PLA2G7GRM2 | |
| SCHEMBL9105930 | 0.73 | FABP4 (0.38) | PLA2G7 | |
| SCHEMBL9889628 | 0.73 | SLC22A12 (0.41) | DAOPLA2G7 | |
| SCHEMBL9107465 | 0.72 | PLA2G7 (0.51) | PLA2G7 | |
| SCHEMBL9107066 | 0.71 | CNR2 (0.39) | PLA2G7TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20140113922-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
| US-8637536-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-01-28 | — | — | US | disclosed |
| US-8637536-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-01-28 | — | — | US | disclosed |
| US-8637536-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-01-28 | — | — | US | disclosed |
| CN-103347864-A | For treating diseases caused by Lp-PLA2Pyrimidone compounds for mediated diseases or conditions | GLAXO GROUP LTD | 2013-10-09 | — | — | CN | disclosed |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113922-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | DAO 1910/4885PLA2G7 6/4885GRM2 2704/4885 |
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | DAO 1910/4885PLA2G7 6/4885GRM2 2704/4885 |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | DAO 803/4885PLA2G7 4/4885GRM2 1669/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | DAO 853/4885PLA2G7 4/4885GRM2 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.